Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?

Essential medicines for hepatitis C: at what price?

(2017) Vijay Shankar Balakrishnan   LANCET INFECTIOUS DISEASES

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

(2016) Swathi Iyengar et al.   PLOS MEDICINE

Access to hepatitis C medicines

(2015) Danny J Edwards et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Estimates on HCV disease burden worldwide - filling the gaps

(2015) H. Wedemeyer et al.   JOURNAL OF VIRAL HEPATITIS

Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health

(2014) Eduard J Beck et al.   ANTIVIRAL THERAPY

Global epidemiology and genotype distribution of the hepatitis C virus infection

(2014) Erin Gower et al.   JOURNAL OF HEPATOLOGY

The changing therapeutic landscape for hepatitis C

(2012) Gregory J Dore   MEDICAL JOURNAL OF AUSTRALIA

Driving a decade of change: HIV/AIDS, patents and access to medicines for all

(2011) Ellen 't Hoen et al.   Journal of the International AIDS Society

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

(2009) Paul Feuerstadt et al.   HEPATOLOGY

Civil Society, Political Mobilization, and the Impact of HIV Scale-Up on Health Systems in Brazil

(2009) Richard G Parker   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES